# Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection

> **NCT01844310** · NA · UNKNOWN · sponsor: **Peking Union Medical College** · enrollment: 300 (estimated)

## Conditions studied

- AIDS/HIV PROBLEM

## Interventions

- **DRUG:** RAL+TDF+LPV/r
- **DRUG:** 3TC+TDF+LPV/r

## Key facts

- **NCT ID:** NCT01844310
- **Lead sponsor:** Peking Union Medical College
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-05
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2013-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01844310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01844310, "Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01844310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*